Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.69 |
| ▸ | MC4R | P32245 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CHKA | P35790 | 5/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16356429 | 1.00 | HDAC6 (0.69) | HDAC6MC4RHRH3LMNACHKA | |
| Hydrochloric Acid SCHEMBL14763998 | 0.98 | HDAC6 (0.68) | HDAC6MC4RHRH3LMNACHKA | |
| Hydrochloric Acid SCHEMBL3272318 | 0.98 | HDAC6 (0.68) | HDAC6MC4RHRH3LMNACHKA | |
| Hydrochloric Acid SCHEMBL846616 | 0.98 | HDAC6 (0.68) | HDAC6MC4RHRH3LMNACHKA | |
| Hydrochloric Acid SCHEMBL3664891 | 0.97 | HDAC6 (0.66) | HDAC6MC4RHRH3LMNACHKA | |
| Hydrochloric Acid SCHEMBL1583152 | 0.97 | HDAC6 (0.66) | HDAC6MC4RHRH3LMNACHKA | |
| Hydrogen Sulfide SCHEMBL27950422 | 0.94 | HDAC6 (0.62) | HDAC6MC4RHRH3LMNACHKA | |
| Hydrochloric Acid SCHEMBL14763461 | 0.92 | HDAC6 (0.61) | HDAC6MC4RHRH3LMNACHKA | |
| SCHEMBL10074441 | 0.91 | HDAC1 (0.62) | HDAC6HRH3LMNAGAATHRB | |
| SCHEMBL15149927 | 0.90 | HDAC6 (0.58) | HDAC6MC4RHRH3LMNACHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850258-B | Synthesis method of masitinib | 东北林业大学 | 2024-09-24 | — | — | CN | claimed |
| CN-115850258-A | Synthesis method of masitinib | 东北林业大学 | 2023-03-28 | — | — | CN | claimed |
| CN-114685428-A | Preparation method of imatinib mesylate | 重庆圣华曦药业股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| EP-3431478-B1 | MICROMOLECULAR LUNG-TARGETING DRUG | YAOPHARMA CO LTD (CN) | 2021-11-17 | — | — | EP | claimed |
| US-10463743-B2 | Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2019-11-05 | — | — | US | claimed |
| EP-3403651-B1 | ISOCORYDINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | LANZHOU INST CHEMICAL PHYSICS CAS (CN) | 2019-10-30 | — | — | EP | claimed |
| US-20190029997-A1 | SMALL MOLECULAR LUNG-TARGETING DRUG | YAOPHARMA CO., LTD. (CN) | 2019-01-31 | — | — | US | claimed |
| EP-3431478-A1 | MICROMOLECULAR LUNG-TARGETING DRUG | Yaopharma Co., Ltd. (CN) | 2019-01-23 | — | — | EP | claimed |
| US-20180334448-A1 | Isocorydine derivatives, preparation method and use thereof | LANZHOU INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2018-11-22 | — | — | US | claimed |
| EP-3403651-A1 | ISOCORYDINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | Lanzhou Institute Of Chemical Physics Chinese Academy of Sciences (CN) | 2018-11-21 | — | — | EP | claimed |
| EP-1313703-B1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-02-13 | — | — | EP | claimed |
| CN-1227230-C | Prodrugs to NMDA receptor ligands | HOFFMANN LA ROCHE (CH) | 2005-11-16 | — | — | CN | claimed |
| CN-1447793-A | Prodrugs to NMDA receptor ligands | HOFFMANN LA ROCHE (CH) | 2003-10-08 | — | — | CN | claimed |
| EP-1313703-A1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-28 | — | — | EP | claimed |
| US-6407235-B1 | A NMDA (N-METHYL-D-ASPARTATE)-RECEPTOR-SUBTYPE SELECTIVE BLOCKERS; PRODRUGS HAVE IMPROVED SOLUBILITY AND ARE HYDROLYZED IN VIVO; FOR EXAMPLE, THE 4-AMINOMETHYL-BENZOIC ACID ESTER OF THE PHENOL, OR THE PHOSPHATE ESTER | HOFFMANN-LA ROCHE INC. | 2002-06-18 | — | — | US | claimed |
| US-20020040037-A1 | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol | EVOTEC INTERNATIONAL GMBH (DE) | 2002-04-04 | — | — | US | claimed |
| WO-2002016321-A1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-28 | — | — | WO | claimed |
| US-5675023-A | VISION DEFECTS; NERVOUS SYSTEM DISORDERS; COMPLICATIONS OF DIABETES | TSUMURA & CO. (JP) | 1997-10-07 | — | — | US | claimed |
| US-5627204-A | ENZYME INHIBITORS FOR TREATMENT OF DIABETES | TSUMURA & COMPANY (JP) | 1997-05-06 | — | — | US | claimed |
| US-5455267-A | For reducing side effects of diabetes | TSUMURA & CO. (JP) | 1995-10-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040037-A1 | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol | HAO2, CYP2B6, CBR1 | HDAC6 1255/4885MC4R 1996/4885HRH3 91/4885 |
| US-20180334448-A1 | Isocorydine derivatives, preparation method and use thereof | CCND2, CCND3, IDH3A | HDAC6 3766/4885MC4R 4580/4885HRH3 6/4885 |
| US-10463743-B2 | Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof | ABCB4, ABCB1, LCAT | HDAC6 752/4885MC4R 4424/4885HRH3 2443/4885 |
| US-20190029997-A1 | SMALL MOLECULAR LUNG-TARGETING DRUG | SLC7A5, SCNN1B, SLC43A1 | HDAC6 91/4885MC4R 3000/4885HRH3 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.